Company news
Faron Pharmaceuticals Oy (LSE:FARN) news
Faron Pharmaceuticals Oy news releases on 6ix. Latest, Jun 2, 2025: Faron Pharmaceuticals Presents Phase II Data from BEXMAB Study at ASCO 2025
Press releases — page 3
Faron Pharmaceuticals Presents Phase II Data from BEXMAB Study at ASCO 2025
June 2, 2025
Faron Pharmaceuticals presents Phase II data ...
June 2, 2025
Faron Announces Publication of Full Phase I BEXMAB Study Data in Lancet Haematology
May 30, 2025
Faron announces publication of full Phase I B...
May 30, 2025
Faron Pharmaceuticals Ltd: Issue of Treasury ...
May 27, 2025
Faron’s Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid Malignancies
May 27, 2025
Faron’s Bexmarilimab demonstrates immune-acti...
May 27, 2025
Faron Announces New Data that Highlight Patient Populations with Cancer that are Most Likely to Benefit from First-in-class Immunotherapy Bexmarilimab
May 23, 2025
Faron announces new data that highlight patie...
May 23, 2025
Faron Pharmaceuticals: Strengthens its busine...
May 21, 2025
Faron Appoints Ralph Hughes as Chief Business Officer (CBO)
May 21, 2025
Faron Appoints Ralph Hughes as Chief Business...
May 21, 2025
Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress
May 15, 2025
Faron Announces Acceptance of Bexmarilimab Da...
May 15, 2025
Faron Pharmaceuticals Presents Promising Phase 1/2 Data from BEXMAB Study at MDS 2025 Plenary Session
May 12, 2025
Faron Pharmaceuticals presents promising Phas...
May 12, 2025
Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025
April 24, 2025
Faron announces acceptance of bexmarilimab Ph...
April 24, 2025
Holding in Company
April 17, 2025
Faron Pharmaceuticals - Positive phase II BEX...
April 15, 2025
Faron Pharmaceuticals: Positive data from BEX...
April 15, 2025
Inside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome
April 15, 2025
Inside Information: Faron Announces Positive ...
April 15, 2025
Faron Pharmaceuticals: Enters into convertibl...
April 3, 2025
Inside Information: Faron enters into an up t...
April 3, 2025
Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress
March 27, 2025
Board Changes
March 21, 2025
Results of the Annual General Meeting, Change of Directors, Decision of the Board Meeting After the AGM
March 21, 2025
Results of the Annual General Meeting, Change...
March 21, 2025
Shareholders’ Nomination Board updates its Recommendation on the Number of Board Members to be Elected and the Persons Proposed to be Elected
March 20, 2025
Shareholders’ Nomination Board updates its re...
March 20, 2025
FDA Grants Orphan Drug Designation
March 3, 2025
Notice of Annual General Meeting
February 28, 2025
Positive EMA Opinion on Orphan Drug Designation
February 27, 2025
Annual Report 2024 published
February 27, 2025
Financial Statement 1 January to 31 December 2024
February 27, 2025
Notice of Financial Statement and Annual Report
February 19, 2025
Holding(s) in Company
February 14, 2025
Change of Broker
February 11, 2025
Results of Oversubscribed Placing
February 6, 2025
Proposed Issue and Placing
February 5, 2025
Final Patient Identified for BEXMAB Phase II Study
January 31, 2025
Faron’s Financial Calendar for 2025
December 13, 2024
Faron presents BEXMAB data at ASH Annual Meeting
December 10, 2024
Interactions with UK Regulatory Authorities
December 2, 2024
Positive Phase 2 Interim Results from BEXMAB Trial
November 27, 2024
Targeting Soluble Clever-1 for Autoimmune Diseases
November 11, 2024
Shareholders’ Nomination Board
November 5, 2024
Faron’s Capital Markets Day 2024
October 22, 2024
Faron announces Capital Markets Day
October 7, 2024